High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light ...

The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC ...

The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...

As a numerical comparison, Keytruda monotherapy achieved a 45% ORR in first-line PD-L1 high patients ... drug conjugates and bispecific antibodies. "ESMO 2024: TIGIT race tightens with first ...

Novartis, meanwhile, handed rights to TIGIT antibody ociperlimab to BeiGene a year ago, two years after paying $300 million upfront for an option on the drug. Like PD-1/PD-L1, TIGIT is thought to ...

GSK and iTeos anti-TIGIT antibody belrestotug showed efficacy in a phase 2 trial in PD-L1-positive non-small cell lung cancer (NSCLC), providing some much-needed positive news for the beleaguered ...

The rate is also almost double the discontinuation rates reported for Roche's TIGIT/PD-L1 combo of tiragolumab and Tecentriq in the same setting, Leerink Partners said. To cut down on unnecessary ...

More than two years after an initial FDA approval in melanoma, Bristol Myers Squibb is moving its PD-1/LAG-3 combo Opdualag ...

At the European Society for Medical Oncology (ESMO) Congress 2024, GSK and iTeos finally provided the first data reveal of their TIGIT inhibitor, belrestotug, in combination with Jemperli (dostarlimab ...

Having said that, it is because this company made a move about a month ago to receive ex-China development and commercial rights to ImmuneOnco's PD-L1/VEGF bispecific antibody known as IMM2510 ...